PYC Therapeutics Secures A$145.8M to Advance Four Rare Disease Drug Trials

• A$145.8 million entitlement offer at $1.25 per share to institutional and retail shareholders
• Chairman Alan Tribe commits $35 million to the raise
• Funds to progress clinical trials for Retinitis Pigmentosa, Autosomal Dominant Optic Atrophy, Polycystic Kidney Disease, and Phelan-McDermid Syndrome
• Capital raise extends cash runway to over A$200 million, funding pipeline through FY27